Skip to content

Study · Non-randomized trial · n = 42 · 2018

7 results

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.

Iepsen EW, Zhang J, Thomsen HS, Hansen EL, Hollensted M, Madsbad S, Hansen T, Holst JJ, Holm JC, Torekov SS

Cell metabolism31 May 2018Cited by 109 (Europe PMC)

PMID29861388 (opens in a new tab)DOI10.1016/j.cmet.2018.05.008 (opens in a new tab)PepBankPUB-29861388
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In obese adults with and without MC4R mutations, liraglutide produced an equal weight loss of 6% in both groups.

    In plain wordsIn obese adults with or without MC4R gene mutations, liraglutide produced the same weight loss of about 6%.

    Peptide
    Liraglutide
    Outcome
    DecreasePercent weight loss in both groups
    Study

    n = 42

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 16 weeksAs given in this study (human).

    Measurements

    Weight loss
    6%
    Both groups

    Source sentences

    Summary
    liraglutide induced an equal, clinically significant weight loss of 6% in both groups
    1 context sentence
    Summary · context
    We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8).
  2. 02HumanNon-randomized trialEfficacy outcome

    In obese adults with and without MC4R mutations, liraglutide decreased total body fat similarly in both groups.

    In plain wordsIn obese adults with or without MC4R gene mutations, liraglutide lowered body fat to a similar degree.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal body fat
    Study

    n = 42

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups
    1 context sentence
    Summary · context
    We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8).
  3. 03HumanNon-randomized trialEfficacy outcome

    In obese adults with and without MC4R mutations, liraglutide decreased waist circumference similarly in both groups.

    In plain wordsIn obese adults with or without MC4R gene mutations, liraglutide shrank waist size to a similar degree.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 42

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups.
    1 context sentence
    Summary · context
    We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8).
  4. 04HumanNon-randomized trialEfficacy outcome

    In obese adults with and without MC4R mutations, liraglutide decreased fasting glucose concentrations similarly in both groups.

    In plain wordsIn obese adults with or without MC4R gene mutations, liraglutide lowered fasting blood sugar to a similar degree.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glucose
    Study

    n = 42

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 mg · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups.
    1 context sentence
    Summary · context
    We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8).
  5. 05HumanNon-randomized trialEfficacy outcome

    In obese adults with and without MC4R mutations, liraglutide decreased postprandial glucose concentrations similarly in both groups.

    In plain wordsIn obese adults with or without MC4R gene mutations, liraglutide lowered blood sugar after meals to a similar degree.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucose
    Study

    n = 42

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 mg · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups.
    1 context sentence
    Summary · context
    We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8).
  6. 06HumanNon-randomized trialEfficacy outcome

    In obese adults without MC4R mutations, liraglutide 3.0 mg for 16 weeks decreased body weight by 6.1 kg.

    In plain wordsIn obese adults without MC4R gene mutations, liraglutide lowered body weight by 6.1 kg over 16 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change in control participants
    Study

    n = 28

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 16 weeksAs given in this study (human).

    Measurements

    Body weight change
    −6.1 kg
    Control participants

    Source sentences

    Summary
    by 6.1 kg ± 1.2 kg in control participants
    1 context sentence
    Summary · context
    We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8).
  7. 07HumanNon-randomized trialEfficacy outcome

    In obese adults with pathogenic MC4R mutations, liraglutide 3.0 mg for 16 weeks decreased body weight by 6.8 kg.

    In plain wordsIn obese adults with MC4R gene mutations, liraglutide lowered body weight by 6.8 kg over 16 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change in MC4R mutation carriers
    Study

    n = 14

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 16 weeksAs given in this study (human).

    Measurements

    Body weight change
    −6.8 kg
    MC4R mutation carriers

    Source sentences

    Summary
    Liraglutide decreased body weight by 6.8 kg ± 1.8 kg in individuals with pathogenic MC4R mutations
    1 context sentence
    Summary · context
    We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT05574439

Young Adults With Early-onset Obesity Treated With Semaglutide

Signe Torekovn = 24630 May 2022 to 1 Apr 2026

Obesity, Adolescent

Trial pageClinicalTrials.govUpdated 8 Jul 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.